111In-Octreoscan SPECT/CT hybrid imaging and 68Ga-DOTANOC PET/CT in neuroendocrine adenoma of the middle ear (NAME)

Mariano Pontico; Viviana Frantellizzi; Laura Cosma; Giuseppe De Vincentis

doi:10.4103/ijri.IJRI_125_20

111In-Octreoscan SPECT/CT hybrid imaging and 68Ga-DOTANOC PET/CT in neuroendocrine adenoma of the middle ear (NAME)

Indian J Radiol Imaging. 2020 Jul-Sep;30(3):400-404. doi: 10.4103/ijri.IJRI_125_20. Epub 2020 Oct 15.

Authors

Mariano Pontico¹, Viviana Frantellizzi², Laura Cosma³, Giuseppe De Vincentis³

Affiliations

¹ Department of Medico-Surgical Sciences and Biotechnologies, Ph.D. Program in Morphogenesis and Tissue Engineering, Rome, Italy.
² Department of Molecular Medicine, Oncology and Anatomical Pathology, Sapienza University of Rome, Viale Regina Elena 324, Rome, Italy.
³ Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Viale Regina Elena 324, Rome, Italy.

Abstract

Neuroendocrine adenoma of the middle ear (NAME) represents a rare tumour consisting of an adenoma with mixed neuroendocrine differentiation. A 40-year-old woman was referred to our attention to further investigate the occurrence of a pathological tissue located in the mastoid process of the left temporal bone depicted by head CT and MRI scans. Histopathological examination revealed an epithelial neoplasm with neuroendocrine differentiation features, consistent with the diagnosis of NAME. In order to obtain an accurate differential diagnosis and confirmation of this rare disease, 111In-Octreoscan single photon emission computed tomography (SPECT)/CT and 68Ga-DOTANOC positron emission tomography (PET)/CT were performed, both showing overexpression of somatostatin receptors and thus corroborating the histopathological findings.

Keywords: 111In-Octreoscan SPECT; 68Ga-DOTANOC PET/CT; NAME; NET; carcinoid; hybrid SPECT/CT imaging; middle ear adenoma.

Publication types

Case Reports